01—Abstract
Summary
Summary of the 10-K filed February 25, 2015. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation's (BSX) 2014 10-K filing highlights a year of revenue growth and strategic acquisitions, alongside significant litigation charges.
Net sales increased by 3% to $7.38 billiona, driven by strong performance in Interventional Cardiology, Electrophysiology, Endoscopy, and Peripheral Interventions. However, the company reported a net loss of $119 million, largely impacted by a $600 million settlement with Johnson & Johnson related to the Guidant acquisition. Excluding these and other charges, adjusted net income was $1.13 billion, or $0.84 per share.
The company continued to execute its five strategic imperatives: strengthening execution to grow share, expanding into high-growth adjacencies, driving global expansion, funding growth initiatives, and developing key capabilities. Key acquisitions during the year included the Interventional Division of Bayer AG and IoGyn, Inc., aimed at strengthening the company's product portfolio and market position. BSX emphasizes its commitment to innovation, investing $817 millionb in R&D.
The company also returned value to shareholders through $125 millionc in share repurchases. Despite ongoing healthcare policy changes and pricing pressures, Boston Scientific maintains an optimistic outlook, focusing on its diverse product portfolio and strategic growth opportunities.
02—Key points
Key Highlights
- Net sales increased by 3% to $7.38 billion in 2014, driven by growth across key business segments.
- Reported a net loss of $119 million, primarily due to a $600 million litigation settlement with Johnson & Johnson.
- Excluding certain charges, adjusted net income was $1.13 billion, or $0.84 per share.
- Completed strategic acquisitions of Bayer AG's Interventional Division and IoGyn, Inc. to enhance product offerings.
- Invested $817 million in Research and Development (R&D) to fuel future innovation.
- Returned $125 million to shareholders through share repurchases.
- Maintains investment-grade credit ratings with all three major credit-rating agencies.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2014, Boston Scientific Corp lost $0.02.
- Revenue$7.46B100.0%
- Cost of revenue−$2.29B30.7%
- Gross profit$5.17B69.3%
- Operating costs−$5.47B73.3%
- Operating income−$301.0M4.0%
- Interest, other & tax$182.0M2.4%
- Net income−$119.0M1.6%
04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 25, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $7.46B$7.14B | +4.5% |
| Cost of Revenue | $2.21B$2.17B | +1.7% |
| Gross Profit | $5.17B$4.97B | +4.0% |
| SG&A Expenses | $2.90B$2.67B | +8.5% |
| Operating Expenses | $5.47B$4.85B | +12.8% |
| Operating Income | -$301.00M$120.00M | −350.8% |
| Interest Expense | $216.00M$324.00M | −33.3% |
| Net Income | -$119.00M-$121.00M | +1.7% |
| EPS (Basic) | $-0.09$-0.09 | 0.0% |
| EPS (Diluted) | $-0.09$-0.09 | 0.0% |
| Shares Outstanding (Basic) | 1.32B1.34B | −1.3% |
| Shares Outstanding (Diluted) | 1.32B1.34B | −1.3% |
05—Questions
Frequently Asked Questions
What was Boston Scientific's overall financial performance in 2014?
In 2014, Boston Scientific reported a 3% increase in net sales to $7.38 billion, demonstrating revenue growth. However, the company recorded a net loss of $119 million, significantly influenced by a $600 million litigation settlement with Johnson & Johnson. When excluding these significant charges and other non-recurring items, adjusted net income was $1.13 billion.
What were the key drivers of revenue growth in 2014?
Revenue growth was primarily driven by strong performance in the Interventional Cardiology segment ($2.057 billion in sales), Cardiac Rhythm Management ($1.912 billion), Endoscopy ($1.323 billion), and Peripheral Interventions ($850 million). Constant currency growth was notable in Interventional Cardiology (+5%), Electrophysiology (+48%), Endoscopy (+5%), and Peripheral Interventions (+7%).
What significant risks does Boston Scientific face according to the 10-K?
The company faces intense competition, rapid technological changes in the medical device industry, and pricing pressures. Risks also include the successful integration of acquired businesses, management of debt levels, potential goodwill and intangible asset impairment charges, changes in healthcare policies and reimbursement rates, and regulatory compliance. Significant litigation and intellectual property disputes are also highlighted as key risks.
How did Boston Scientific manage its debt and capital in 2014?
Boston Scientific maintained total debt of $4.262 billion as of December 31, 2014. The company had $587 million in cash and cash equivalents and access to a $2.0 billion revolving credit facility. It held investment-grade ratings from all three major credit rating agencies, reflecting its financial strategy and performance.
06—Continue